肺动脉高压市场基于(关键地区、市场参与者、规模和份额)- 到 2031 年的预测

  • Report Code : TIPRE00005221
  • Category : Pharmaceuticals
  • Status : Published
  • No. of Pages : 174
Buy Now

肺动脉高压市场预计将从2021年的73.6989亿美元增长到2028年的1088908万美元;预计 2022 年至 2028 年复合年增长率为 5.8%。

肺动脉高压市场根据药物、类型、给药途径、分销渠道和地理位置进行细分。该报告提供了肺动脉高压市场的深入信息和分析,强调了各地区领先市场参与者的市场动态、趋势、机会和竞争格局分析等各种参数。它还包括COVID-19大流行对各地区肺动脉高压市场的影响分析。

战略展望

市场展望

肺动脉高压药物的批准增加产品 高血压药物推动市场增长

  • 2022 年 9 月,东丽工业公司 (Toray Industries, Inc.) 的 Careload 获得中国国家药品监督管理局 (NMPA) 批准治疗肺动脉高压(PAH)的片剂。 Careload 是贝前列素钠(一种前列环素 (PGI2) 衍生物)的缓释制剂,口服。
  • 2022 年 5 月,联合治疗公司获得美国食品和药物管理局 (FDA) 批准 Tyvaso DPI(曲前列环素)。吸入粉末用于治疗与间质性肺病(PH-ILD;WHO 第 3 组)和肺动脉高压(PAH;WHO 第 1 组)相关的肺动脉高压,以提高运动能力。
  • 2021 年 11 月,美国 FDA 批准授予 Yutrepia(曲前列环素)吸入粉剂临时批准。 Yutrepia 适用于治疗 PAH 并提高患有纽约心脏协会 (NYHA) 功能性 II-III 级症状的成年患者的运动能力。
  • 截至 2021 年 7 月,强生公司旗下杨森制药公司已批准使用 Yutrepia。 Johnson 获得 FDA 批准 UPTRAVI(selexipag)静脉(IV)注射治疗 PAH; WHO I 组,用于暂时无法接受口服治疗的 WHO 功能分级 (FC) II-III 成年患者。
  • 2021 年 8 月,Aerami Therapeutics, Inc. 宣布 FDA 授予孤儿药公司资格指定药物伊马替尼用于治疗 PAH 患者。 AER:901 是一种用于治疗 PAH 的吸入伊马替尼的药物器械组合候选产品,目前正在进行 1 期试验,计划于 2021 年底完成。

肺动脉药物的批准不断增加世界各地的高血压药物推动了肺动脉高压市场的增长。

基于药物的信息

根据药物,肺动脉高压市场分为内皮素受体拮抗剂(时代)。 )、前列环素和前列环素类似物、sGC 刺激剂和 pde-5 测试条。前列环素和前列环素类似物细分市场在 2021 年占据最大的市场份额,预计 2022-2028 年复合年增长率最高。前列环素是一种小类花生酸脂质分子,也称为前列腺素 I-2 (PGI-2),由内皮细胞产生并局部作用,抑制血小板活化并引起血管舒张。前列环素可扩张血管,通过防止血管平滑肌细胞增殖来改善血流,并通过抑制血小板聚集来防止血液凝固。前列环素类似物已被开发用于治疗 PAH。前列环素 PAH 类似物是前列环素的合成形式,前列环素是体内产生的天然物质。受肺动脉高压影响的患者的前列环素水平往往会降低,从而导致血管收缩和高血压。前列环素 PAH 类似物补充了天然前列环素的需求并模仿了其作用,以降低肺动脉高压并减少相关症状。

肺动脉高压市场,按药物划分:2021-2028

信息基于类型

根据类型,肺动脉高压市场分为品牌药和非专利药。品牌细分市场在 2021 年占据了更高的市场份额,预计在预测期内将实现更高的复合年增长率。制药公司以特定名称或商标销售品牌药物,并受专利保护。品牌药物可以通过处方或非处方药购买。 Riociguat 以商品名 Adempas 销售,是拜耳的可溶性鸟苷酸环化酶刺激药物。它用于治疗两种形式的肺动脉高压:慢性血栓栓塞性肺动脉高压和肺动脉高压。

基于给药途径的信息

根据给药途径,肺动脉高压高血压市场分为口服、静脉/皮下和吸入。口腔细分市场在 2021 年占据最大的市场份额,预计在预测期内复合年增长率最高。用于治疗中度至重度症状性 PAH 的口服药物包括西地那非和内皮素 (ET) 受体拮抗剂 (ARE)、波生坦和西他生坦 (sitaxsentan) 以及阿布里生坦口服 ET(A) 受体选择性 ERA。),具有更大的亲和力对于ET受体的作用优于波生坦。此外,用于治疗 PAH 的新型口服药物包括马西替坦、利奥西呱和曲前列环素。 Ambrisentan 是一种内皮素受体拮抗剂,适用于治疗 PAH; WHO 第 1 组和延迟临床恶化。安立生坦与他达拉非联用可降低因 PAH 恶化而导致疾病进展和住院的风险,并提高运动能力。

基于分销渠道的信息

基于分销渠道的信息分销渠道

根据分销渠道,肺动脉高压市场分为医院药房和诊所、网上药房和零售药房。医院诊所和药房部门在 2021 年占据最大的市场份额,预计在预测期内复合年增长率最高。医院药房致力于维持并持续改进患者的药物管理和药学护理,使其达到医院环境中的最高标准。该领域的药剂师负责配药、进行质量测试、配制和重新配制剂型、监测、报告药物安全性以及准备药物预算。

医药市场的参与者肺动脉高压采用有机战略,例如产品推出和扩张,以扩大其在全球的影响力和产品组合并满足不断增长的需求。市场上常见的无机增长策略是伙伴关系和协作。这些增长战略使市场参与者能够扩大业务并改善其地域影响力。此外,收购、合作和其他增长战略有助于增强公司的客户群并扩大其产品组合。

  • 2022 年 9 月,Lupin 推出了口服西地那非。经美国FDA批准暂停在美国市场销售。该药物是 Viatris Specialty LLC 口服混悬液 Revatio 的通用版本。口服混悬液西地那非可治疗 PAH。
  • 2021 年 2 月,Aerami Therapeutics, Inc. 与杭州昌斯制药有限公司(Chance)签署了独家开发和许可协议,由 Aeromi 开发和商业化该药物。用于治疗中国大陆、香港、澳门和台湾地区 PAH 的候选器械组合产品(“AER-901”)。根据协议,Chance 负责用于 PAH 的 AER-901 在该地区的整体开发和商业化。

公司简介

  • Johnson & ;约翰逊
  • 吉利德科学公司
  • 联合治疗公司
  • 拜耳股份公司
  • Aerami Therapeutics Holdings Inc
  • 拜耳股份公司
  • Aerami Therapeutics Holdings Inc
  • 拜耳股份公司< /li>
  • Aerami Therapeutics Holdings Inc ;                 
  • 诺华公司       葛兰素史克公司                             &n公共服务提供商;             
  • 卢平有限公司           
  • 辉瑞公司
  • 梯瓦制药工业有限公司
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


What is pulmonary arterial hypertension?

Pulmonary arterial hypertension (PAH) is a rare, progressive disorder characterized by high blood pressure (hypertension) in the lungs' arteries. The increased pressure in the vessels may be caused by an obstruction in the lung's small arteries for various reasons. The exact cause of PAH is unknown, and although treatable, there is no permanent cure for the disease. PAH usually affects women between the ages of 30-60. However, individuals with PAH may go years without a diagnosis, either because the symptoms may be mild, nonspecific, or only present during demanding exercise.

What are the driving factors for global pulmonary arterial hypertension worldwide?

The factors driving the growth of pulmonary arterial hypertension are the growing incidence of pulmonary arterial hypertension and the rising approvals of pulmonary arterial hypertension drugs.

What are the restraining factors for global pulmonary arterial hypertension worldwide?

The side effects of drugs used for treating pulmonary arterial hypertension are expected to restrict the pulmonary arterial hypertension market growth during the forecast period.

Who are the major players in pulmonary arterial hypertension across the globe?

Pulmonary arterial hypertension majorly consists of the players, such as Johnson & Johnson, Gilead Sciences Inc, United Therapeutics Corp, Bayer AG, Aerami Therapeutics Holdings Inc, Novartis AG, GSK Plc, Teva Pharmaceutical Industries Ltd, Lupin Ltd, and Pfizer Inc.

Which segment is dominating the pulmonary arterial hypertension market?

Based on drugs, the pulmonary arterial hypertension market is segmented into prostacyclin and prostacyclin analogs, endothelin receptor antagonists (ERAs), sGC stimulators, and pde-5 dipsticks. In 2021, the prostacyclin and prostacyclin analogs segment accounted for a larger market share. Also, the same segment is anticipated to register a higher CAGR during the forecast period as the PAH prostacyclin analogs are used as medications to treat pulmonary arterial hypertension (PAH), a condition of high blood pressure in the arteries that carry deoxygenated blood from the heart to the lungs.

Which region is dominating the pulmonary arterial hypertension market?

The global pulmonary arterial hypertension based on regions is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America. In 2021, North America held the largest market share. However, the Asia Pacific region is estimated to grow at the fastest CAGR of 6.5% during the forecast period.

The List of Companies - Butterfly Needles Market

  1. Johnson & Johnson
  2. Gilead Sciences Inc
  3. United Therapeutics Corp
  4. Bayer AG
  5. Aerami Therapeutics Holdings Inc
  6. Novartis AG
  7. GSK Plc
  8. Teva Pharmaceutical Industries Ltd
  9. Lupin Ltd
  10. Pfizer Inc

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports